Ger­man biotech CatalYm rais­es $150M to re­pur­pose obe­si­ty tar­get for can­cer

CatalYm has racked up $150 mil­lion in an over­sub­scribed Se­ries D to ad­vance its an­ti­body drug that neu­tral­izes GDF15 — a tar­get pre­vi­ous­ly ex­plored by oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER